BRIEF-AstraZeneca Announces Update On U.S. Regulatory Review Of Roxadustat In Anaemia Of Chronic Kidney Disease

AstraZeneca PLC: * UPDATE ON US REGULATORY REVIEW OF ROXADUSTAT IN ANAEMIA OF CHRONIC KIDNEY DISEASE

* NDA REMAINS UNDER REGULATORY REVIEW, WITH FDA HAVING SET A NEW ACTION DATE OF 20 MARCH 2021 * CO AND FIBROGEN COMMITTED TO WORKING WITH FDA Source text for Eikon: Further company coverage: